Metabolic strugGLS after FLT3 inhibition in AML

Taylor, Samuel J.; Steidl, Ulrich

doi:10.1182/blood-2018-03-836338

Cited by 1 publication

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metabolic reprogramming has been considered as one of the hallmarks of cancer. FLT3 inhibition can induce metabolic reprogramming (307). Cells carrying FLT3-ITD display a differential metabolic profile compared with wildtype FLT3-expressing cells (296), suggesting that a deeper understanding of FLT3-ITD-induced metabolic regulation can lead to alternative therapeutic approaches.…”

Section: E Flt3 Inhibition and Feedback Regulationmentioning

confidence: 99%

FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications

Kazi

Rönnstrand

2019

Physiological Reviews

132

147

View full text Add to dashboard Cite

FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase that is expressed almost exclusively in the hematopoietic compartment. Its ligand, FLT3 ligand (FL), induces dimerization and activation of its intrinsic tyrosine kinase activity. Activation of FLT3 leads to its autophosphorylation and initiation of several signal transduction cascades. Signaling is initiated by the recruitment of signal transduction molecules to activated FLT3 through binding to specific phosphorylated tyrosine residues in the intracellular region of FLT3. Activation of FLT3 mediates cell survival, cell proliferation, and differentiation of hematopoietic progenitor cells. It acts in synergy with several other cytokines to promote its biological effects. Deregulated FLT3 activity has been implicated in several diseases, most prominently in acute myeloid leukemia where around one-third of patients carry an activating mutant of FLT3 which drives the disease and is correlated with poor prognosis. Overactivity of FLT3 has also been implicated in autoimmune diseases, such as rheumatoid arthritis. The observation that gain-of-function mutations of FLT3 can promote leukemogenesis has stimulated the development of inhibitors that target this receptor. Many of these are in clinical trials, and some have been approved for clinical use. However, problems with acquired resistance to these inhibitors are common and, furthermore, only a fraction of patients respond to these selective treatments. This review provides a summary of our current knowledge regarding structural and functional aspects of FLT3 signaling, both under normal and pathological conditions, and discusses challenges for the future regarding the use of targeted inhibition of these pathways for the treatment of patients.

show abstract

Section: E Flt3 Inhibition and Feedback Regulationmentioning

confidence: 99%